Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 7Recruiting 3Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 8INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 3

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × tipiracil × Clear all
NCT07549412 2026-05-08

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

EMD Serono

Phase 3 Recruiting
1,020 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06992258 2026-03-17

FRUITION

Criterium, Inc.

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07361003 2026-01-22

A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 3 Recruiting
464 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡